Investigation of another combination, daratumumab (anti-CD38 mAb) with PD-1 or PD-L1 inhibitors, was abandoned based on the unsatisfying results from a phase 1b/2 LUC2001 study of atezolizumab with or without daratumumab for advanced or metastatic non-small-cell lung cancer (NCT03023423) (Cohen et al., 2021). The gene discussed is CD38; the disease is non-small cell lung carcinoma.